S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)

Nevro (NVRO) Stock Forecast & Price Target

$14.51
+0.29 (+2.04%)
(As of 05:26 PM ET)

Nevro Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 13 Analyst Ratings

Analysts' Consensus Price Target

$23.23
60.10% Upside
High Forecast$40.00
Average Forecast$23.23
Low Forecast$15.00
TypeCurrent Forecast
3/5/23 to 3/4/24
1 Month Ago
2/3/23 to 2/3/24
3 Months Ago
12/5/22 to 12/5/23
1 Year Ago
3/5/22 to 3/5/23
Consensus Rating
Hold
Hold
Hold
Reduce
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
2 Buy rating(s)
4 Buy rating(s)
2 Buy rating(s)
Hold
11 Hold rating(s)
10 Hold rating(s)
7 Hold rating(s)
6 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
3 Sell rating(s)
Consensus Price Target$23.23$24.00$26.67$50.30
Predicted Upside60.10% Upside17.42% Upside34.70% Upside17.43% Upside
Get Nevro Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NVRO and its competitors with MarketBeat's FREE daily newsletter.


NVRO Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NVRO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Nevro Stock vs. The Competition

TypeNevroMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.68
2.48
Consensus RatingHoldModerate BuyHold
Predicted Upside65.70% Upside877.70% Upside6.65% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/22/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$23.00 ➝ $19.00+15.15%
2/22/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$20.00 ➝ $17.00+3.03%
2/22/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
1/12/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Sector Perform$23.00 ➝ $20.00+6.95%
12/22/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$22.00 ➝ $23.00+8.03%
12/21/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold$23.00+9.21%
11/2/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$23.00 ➝ $18.00+20.00%
11/2/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetUnderweight ➝ Underweight$24.00 ➝ $15.00
11/2/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$23.00 ➝ $18.00+20.00%
8/21/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$24.00 ➝ $21.00+11.70%
8/2/2023JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$75.00 ➝ $40.00+62.14%
7/17/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$40.00 ➝ $30.00+23.92%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 05:48 PM ET.












NVRO Price Target - Frequently Asked Questions

What is Nevro's consensus rating and price target?

According to the issued ratings of 13 analysts in the last year, the consensus rating for Nevro stock is Hold based on the current 1 sell rating, 11 hold ratings and 1 buy rating for NVRO. The average twelve-month price prediction for Nevro is $23.23 with a high price target of $40.00 and a low price target of $15.00. Learn more on NVRO's analyst rating history.

Do Wall Street analysts like Nevro more than its competitors?

Analysts like Nevro less than other Medical companies. The consensus rating for Nevro is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how NVRO compares to other companies.

Is Nevro being downgraded by Wall Street analysts?

Over the previous 90 days, Nevro's stock had 3 downgrades by analysts.

Does Nevro's stock price have much upside?

According to analysts, Nevro's stock has a predicted upside of 19.03% based on their 12-month stock forecasts.

What analysts cover Nevro?

Stock Ratings Reports and Tools

This page (NYSE:NVRO) was last updated on 3/4/2024 by MarketBeat.com Staff